<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417923</url>
  </required_header>
  <id_info>
    <org_study_id>0042-11-MMC</org_study_id>
    <nct_id>NCT01417923</nct_id>
  </id_info>
  <brief_title>The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain</brief_title>
  <official_title>The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D3 is produced in the skin following exposure to UVB light from the sun or artificial&#xD;
      sources, and occurs naturally in a small range of foods.More recently, several reports&#xD;
      underlined the impact of vitamin D on the prevalence and consequences of inadequate vitamin D&#xD;
      intake and the research supporting its benefits for alleviating chronic musculoskeletal pain&#xD;
      and fatigue syndromes in outpatients. Experts have recommended that vitamin D inadequacy&#xD;
      should be addressed in all patients with bone or joint pain, myalgia, fibromyalgia, or&#xD;
      chronic fatigue syndrome. It appears that soothing the daily musculoskeletal pain by&#xD;
      supplementation of vitamin D may be a simple, well tolerated, and cost-effective modality.&#xD;
&#xD;
      Aim of study:&#xD;
&#xD;
      To study the potential therapeutic effects of vitamin D supplementation on patients with&#xD;
      persistent musculo-skeletal pain. Clinicalparameters, visual analog score,short form McGill&#xD;
      Pain Questionnaire,patient global perceived effect, quality of life assessed by SF-36&#xD;
      Questionnaire and laboratory parameters, the levels of 25 OH-Vitamin D, CRP, IL-6, IL-8, TNF&#xD;
      and prostaglandin E will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immune and clinical impacts of vitamin D in patients with chronic musculo-skeletal pain&#xD;
&#xD;
      Background Vitamin D is a group of fat-soluble secosteroids, the two major physiologically&#xD;
      relevant forms are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D&#xD;
      without a subscript refers to either D2 or D3 or both. Vitamin D3 is produced in the skin&#xD;
      following exposure to UVB light from the sun or artificial sources, and occurs naturally in a&#xD;
      small range of foods. Vitamin D is carried in the bloodstream to the liver, where it is&#xD;
      converted into the prohormone calcidiol. Circulating calcidiol may then be converted into&#xD;
      calcitriol, the biologically active form of vitamin D, either in the kidneys or by&#xD;
      monocyte-macrophages in the immune system. When synthesized by monocyte-macrophages,&#xD;
      calcitriol acts locally as a cytokine, defending the body against microbial invaders (1).&#xD;
&#xD;
      When synthesized in the kidneys, calcitriol circulates as a hormone, regulating among other&#xD;
      things, the concentration of calcium and phosphate in the bloodstream, promoting the healthy&#xD;
      mineralization, growth and remodeling of bone, and also vital to the normal function of the&#xD;
      different arms of the immune system (1;2).&#xD;
&#xD;
      Vitamin D receptor activation in the intestine, bone, kidney, and parathyroid gland cells&#xD;
      leads to the maintenance of calcium and phosphorus levels in the blood (with the assistance&#xD;
      of parathyroid hormone and calcitonin) and to the maintenance of bone content. Vitamin D&#xD;
      increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Vitamin D&#xD;
      is involved in the biosynthesis of neurotrophic factors, synthesis of nitric oxide synthase,&#xD;
      and increased glutathione levels. Adequate vitamin D may also be associated with healthy hair&#xD;
      follicle growth cycles (3). Vitamin D insufficiency can result in thin and brittle bones,&#xD;
      whereas sufficiency prevents rickets in children and osteomalacia in adults and helps to&#xD;
      protect elderly from osteoporosis. Vitamin D has also direct on muscle strength and function&#xD;
      (4;5). Nevertheless, there is no persuasive evidence of lower vitamin D status in chronic&#xD;
      pain sufferers.&#xD;
&#xD;
      There are also associations between low 25(OH)D levels and peripheral vascular disease (6),&#xD;
      certain cancers (7-10), multiple sclerosis (11), rheumatoid arthritis (12-15), juvenile&#xD;
      diabetes (16-18), Parkinson's and Alzheimer's disease (19;20). However these associations&#xD;
      were found in observational studies and vitamin D vitamin supplements have not been&#xD;
      demonstrated to reduce the risks of these diseases.&#xD;
&#xD;
      More recently, several reports underlined the impact of vitamin D on the prevalence and&#xD;
      consequences of inadequate vitamin D intake and the research supporting its benefits for&#xD;
      alleviating chronic musculoskeletal pain and fatigue syndromes in outpatients. There are&#xD;
      extensive reports of pain worldwide and much of it is chronic, lasting 3 or more months,&#xD;
      primarily involving muscles, bones and joints. In the United States, more than half of all&#xD;
      adults participating in surveys have reported long term persistent or intermittent pain, with&#xD;
      the lower and upper back, neck, shoulders, hips, and knees mentioned most frequently (21).&#xD;
      For lower-back pain alone, an annual incidence of 50% and a lifetime prevalence of up to 80%&#xD;
      have been reported (22). In more than 8 out of 10 cases, the causes are nonspecific, without&#xD;
      evidence of injury, disease, or anatomical defect (23;24). More than a quarter (28%) of&#xD;
      patients with chronic pain rate the effectiveness of medical treatments as poor, and most&#xD;
      (77%) believe that new options are needed to treat their pain (25-27). It appears that&#xD;
      soothing the daily musculoskeletal pain by supplementation of vitamin D may be a simple, well&#xD;
      tolerated, and cost-effective modality. Experts have recommended that vitamin D inadequacy&#xD;
      should be addressed in all patients with bone or joint pain, myalgia, fibromyalgia, or&#xD;
      chronic fatigue syndrome (28;29). However, this seems to be unknown or overlooked by many&#xD;
      healthcare providers. Research on vitamin D is still an emerging field, and there are&#xD;
      divergent opinions among experts regarding many aspects of vitamin D pharmacology, function,&#xD;
      and adequate intake needed for good health. While further research is needed, the clinical&#xD;
      evidence to date recommending vitamin D supplementation for musculoskeletal pain and&#xD;
      associated symptoms seems to be growing. In 3670 patients taking part in different studies&#xD;
      with musculoskeletal pain significant vitamin D inadequacies were found in 48% to 100%. A&#xD;
      study from the Mayo Clinic reported that a whopping 93% of patients with &quot;chronic nonspecific&#xD;
      pain syndromes&quot; had deficient levels of vitamin D (30). When supplementation was provided for&#xD;
      improving vitamin D status, pain and/or muscle weakness were resolved or at least subsided in&#xD;
      most cases, and there were associated improvements in physical functioning.&#xD;
&#xD;
      A recently reported prospective study of 51 patients with type 2 diabetes and associated&#xD;
      chronic, painful neuropathy found that conservative vitamin D supplementation (about 2000&#xD;
      IU/day) for 3 months resulted in nearly a 50% decrease in pain scores, with symptoms&#xD;
      improving from &quot;distressing&quot; to &quot;mild&quot; on average (31). There had been an earlier case report&#xD;
      of a patient with type 1 diabetes whose severe neuropathy had confined her to a wheelchair.&#xD;
      This patient's aches and pains were resolved by high-dose vitamin D supplementation, and she&#xD;
      reportedly was able to walk unassisted within 4 weeks (32). Other therapies need not be&#xD;
      discontinued during a trial of vitamin D &quot;analgesia.&#xD;
&#xD;
      Miller et al (33) evaluated in a cohort from the Baltimore Hip Studies, women aged &gt;65 years&#xD;
      were at baseline and 2, 6, and 12 months after hip fracture repair. Serum at baseline was&#xD;
      analyzed for 25-hydroxyvitamin D [25(OH)D] and serum from all time points was analyzed for&#xD;
      IL-6, women with vitamin D deficiency at the time of hip fracture had higher serum IL-6&#xD;
      levels in the year after hip fracture.&#xD;
&#xD;
      Aim of study To study the potential therapeutic effects of vitamin D supplementation on&#xD;
      patients with persistent musculo-skeletal pain. Clinical and laboratory parameters will be&#xD;
      assessed.&#xD;
&#xD;
      Methods We enrolled 80 patients of the age 18-80 years suffering from chronic&#xD;
      musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6&#xD;
      months. The enrollees will be randomized in a double-blinded manner into the two following&#xD;
      groups: Group 1 will receive daily doses of 4000 units of vitamin D ( 4 drops of 1,000 each)&#xD;
      and Group 2 will receive a placebo. Written informed consent will be obtained from all&#xD;
      participating patients.&#xD;
&#xD;
      On the day of recruitment blood will be drawn in order to determine the levels of 25&#xD;
      OH-Vitamin D, CRP, IL-6, IL-8, TNF and prostaglandin E2. Vitamin D or placebo will be taken&#xD;
      for 6 weeks on top of the individual's daily medications. A second blood analysis will be&#xD;
      conducted following the 6 week duration.&#xD;
&#xD;
      Additional outcome measures pain intensity assessed by visual analog score (VAS) (0 = no&#xD;
      pain, 10 = worst imaginable pain), short form McGill Pain Questionnaire (SMPQ), patient&#xD;
      global perceived effect (PGPE), scored by the patient on a 7-point Likert scale (from very&#xD;
      bad to very good), quality of life assessed by SF-36 Questionnaire will be evaluated at base&#xD;
      line, 6 weeks, 12 weeks and 6 months after the inclusion . At 12 weeks period a third 25&#xD;
      OH-Vitamin D blood level will be measured. Rescue medication will be provided as paracetamol&#xD;
      325mg+codein 15 mg. Consumption of pain medication will be recorded during the study and 2&#xD;
      week intervals. Adverse events will be recorded on each 6 weeks period and on patient report.&#xD;
&#xD;
      The vitamin D levels will be assessed by using the commercial kit, LIAISONÂ® 25-OH vitamin D&#xD;
      Assay (310900) (Cardinal Health, Inc., Dublin, OH, USA). The method for quantitative&#xD;
      determination of 25-OH vitamin D is a direct, competitive chemiluminescence immunoassay.&#xD;
&#xD;
      The other assays will be assessed by ELISA kits. Statistics will be performed using the SPSS&#xD;
      18th edition using the Student's t-test or the Chi-Square test and if appropriate with&#xD;
      Fisher's exact test. To adjust for differences in the baseline values, the analyses will be&#xD;
      performed by using a multivariate logistic regression model. Consumption of medication will&#xD;
      be compared using the Man-Whitney U test. Significance will be regarded if the p values will&#xD;
      be lower than 0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serologic inflamatory responses with prolong vitamin D therapy</measure>
    <time_frame>6 weeks</time_frame>
    <description>On the day of recruitment blood will be drawn in order to determine the levels of 25 OH-Vitamin D, CRP, IL-6, IL-8, TNF and prostaglandin E2. Vitamin D or placebo will be taken for 6 weeks on top of the individual's daily medications. A second blood analysis will be conducted following the 6 week duration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Chronic Pain Syndrome</condition>
  <condition>Inflammatory Response</condition>
  <arm_group>
    <arm_group_label>vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We enrolled 80 patients of the age 18-80 years suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months. The 40 patients will receive daily doses of 4000 units of vitamin D for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>P.O.4000 units Vit D per day for 6 weeks</description>
    <arm_group_label>vitamin D</arm_group_label>
    <other_name>VIT D &quot;SOLGAR&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  We enrolled patients suffering from chronic musculo-skeletal pain (low back pain,&#xD;
             fibromyalgia, chronic widespread pain) at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with low compliance&#xD;
&#xD;
          -  Allergy for vit D&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meir Bennun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Israel:Clalit Health Services, Meir Medical Center, PAIN CLINIC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meir Ben-nun, MD</last_name>
      <phone>97297472651</phone>
      <email>meir.ben-nun@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Sergey Makarov, MD</last_name>
      <phone>97297471545</phone>
      <email>sergey.makarov@clalit.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>November 4, 2012</last_update_submitted>
  <last_update_submitted_qc>November 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic musculo-skeletal pain</keyword>
  <keyword>therapeutic&amp;serology effects of vitamin D</keyword>
  <keyword>CRP, IL-6, IL-8, TNF and prostaglandin E2</keyword>
  <keyword>patients suffering from chronic musculo-skeletal pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

